Literature DB >> 8697321

Combined fine-needle aspiration, physical examination and mammography in the diagnosis of palpable breast masses: their relation to outcome for women with primary breast cancer.

J L Steinberg1, M E Trudeau, D E Ryder, E Fishell, J A Chapman, D R McCready, E B Fish, G Y Hiraki, T M Ross, L A Lickley.   

Abstract

OBJECTIVE: To examine the combined and individual predictive values of fine-needle aspiration (FNA), physical examination (PE) of the breast and mammography (the "triple test") in diagnosing breast cancer in relation to the results of open surgical biopsy.
DESIGN: A study of the records of patients who received both FNA and open surgical biopsy for the same palpable breast lump. The results of diagnostic assessment and open surgical biopsy were categorized as positive or negative. Concordance (percentage of tests found to be correct at biopsy), sensitivity, specificity (percentage of patients without breast cancer for whom the diagnostic test was negative) and positive predictive value (percentage of patients with a positive test found to have breast cancer) were determined for the triple test for each diagnostic modality. In addition, prognostic variables (tumour size, node positivity, estrogen and progesterone receptor status) and outcomes were assessed in patients with a diagnosis of breast cancer.
SETTING: A university-affiliated general hospital with a special focus on women's health. PATIENTS: Of 290 patients who had both FNA and open surgical biopsy, 191 underwent all three diagnostic procedures. MAIN OUTCOME MEASURES: The diagnostic accuracy of FNA, PE and mammography to permit preoperative definitive therapy or to allow observation without mandating open surgical biopsy.
RESULTS: In 81 patients all three diagnostic modalities were in agreement for a diagnosis of either benign or malignant disease; the concordance for the triple test was 98.8% specificity was 100% and sensitivity was 95.5%. Nodal status, tumour size and outcome were similar whether or not the triple test was positive, but, interestingly, when the triple-test results were positive, estrogen (p < 0.05) and progesterone (p < 0.03) receptor values were more likely to be negative.
CONCLUSIONS: When all three diagnostic modalities were in agreement for a diagnosis of malignant disease, the combination of FNA, PE and mammography had excellent concordance with the results of open surgical biopsy, and in this situation definitive treatment may be carried out. If all three modalities are in agreement for a diagnosis of benign disease, a period of close observation with repetition of FNA may be safely entertained. Lack of concordance of the three diagnostic modalities mandates biopsy. Triple-test positively does not predict a worse outcome.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8697321      PMCID: PMC3950138     

Source DB:  PubMed          Journal:  Can J Surg        ISSN: 0008-428X            Impact factor:   2.089


  5 in total

1.  INVESTIGATION OF BREAST LUMPS: AN EVALUATION.

Authors:  A Kumar; L S Vohra; S Bhargava; P S Reddy
Journal:  Med J Armed Forces India       Date:  2017-06-26

2.  Is it Necessary to Excise All Breast Lesions? Experience from a University-Based Breast Unit.

Authors:  Char-Hong Ng; Taib Nur-Aishah; Cheng-Har Yip
Journal:  Malays Fam Physician       Date:  2009-08-31

Review 3.  The educational utility of simulations in teaching history and physical examination skills in diagnosing breast cancer: a review of the literature.

Authors:  Jory S Simpson
Journal:  J Breast Cancer       Date:  2014-06-27       Impact factor: 3.588

4.  Triple test score for the evaluation of invasive ductal and lobular breast cancer.

Authors:  Zsofia Egyed; Balázs Járay; Janina Kulka; Zoltán Péntek
Journal:  Pathol Oncol Res       Date:  2008-08-28       Impact factor: 3.201

5.  Triple assessment in the diagnosis of breast cancer in Kashmir.

Authors:  Masooda Jan; Javeed Ahmad Mattoo; Nazir Ahmad Salroo; Shahnawaz Ahangar
Journal:  Indian J Surg       Date:  2010-07-01       Impact factor: 0.656

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.